Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial
Liang, JH; Wang, L; Zhu, HY; Qian, J; Liao, H; Wu, JZ; Xia, Y; Wu, W; Cao, L; Fan, L; Li, JY; Xu, W
Li, JY; Xu, W (corresponding author), Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Dept Hematol, Nanjing, Jiangsu, Peoples R China.; Li, JY; Xu, W (corresponding author), Nanjing Med Univ, Key Lab Hematol, Nanjing, Jiangsu, Peoples R China.; Li, JY; Xu, W (corresponding author), Collaborat Innovat Ctr Canc Personalized Med, Nanjing, Jiangsu, Peoples R China.
HAEMATOLOGICA, 2020; 105 (1): E29
